Literature DB >> 2167335

Antibodies to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children.

P S LaRussa1, A A Gershon, S P Steinberg, S A Chartrand.   

Abstract

A dot ELISA was used to analyze the antibody response to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children who either developed natural varicella or received the live attenuated varicella vaccine. Both groups of children showed an antibody response to these viral glycoproteins. The antibody response to all three glycoproteins showed excellent persistence over the 3-year period of study. None of the glycoproteins provoked an antibody response that could be shown to correlate with protection from breakthrough varicella after household exposure to chickenpox or from zoster in leukemic vaccinees.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167335     DOI: 10.1093/infdis/162.1.627

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.

Authors:  Charles Grose; Young Juhn
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

3.  Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: evolution of genotypes with an accelerated cell spread phenotype.

Authors:  Charles Grose; Shaun Tyler; Geoff Peters; Joanne Hiebert; Gwen M Stephens; William T Ruyechan; Wallen Jackson; Johnathan Storlie; Graham A Tipples
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

5.  Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Authors:  Yun Hwa Kim; Ji Young Hwang; Hye Min Shim; Eunsil Lee; Songyong Park; Hosun Park
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

6.  Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Authors:  Nicole L Sullivan; Morgan A Reuter-Monslow; Janet Sei; Eberhard Durr; Carl W Davis; Cathy Chang; Megan McCausland; Andreas Wieland; David Krah; Nadine Rouphael; Aneesh K Mehta; Mark J Mulligan; Bali Pulendran; Rafi Ahmed; Kalpit A Vora
Journal:  J Virol       Date:  2018-06-29       Impact factor: 6.549

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.